{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:37:42Z","timestamp":1790105862173,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of transthyretin stabilisation in cardiac transthyretin amyloidosis (ATTR-CM) has been demonstrated in a clinical trial setting, but little is known about treatment decision-making in the real world. Particularly, initiating or discontinuing specific therapy is challenging in early and advanced disease. We evaluated current decision pathways for tafamidis in ATTR-CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre retrospective study included consecutive patients from 15 tertiary centres in Germany in whom ATTR-CM was newly diagnosed between January and June 2024, as well as patients, in whom tafamidis treatment was discontinued during this period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 516 patients with newly established ATTR-CM included in the present analysis, tafamidis was initiated in 414 (80%). The 99 patients without recommendation for tafamidis were older (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), had a higher amyloidosis disease stage (NAC score), worse NYHA class (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and higher NT-proBNP levels (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) compared to those with tafamidis initiation. During the same observation period, tafamidis therapy was discontinued in 28 ATTR-CM patients. Treatment decisions were mainly taken by an interdisciplinary board (73% of centres). The most frequent reasons for not starting or stopping tafamidis were \u2018frailty\u2019 (47%\/61%) and \u2018life expectancy or comorbidity\u2019 (38%\/43%), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this multicentre analysis, treatment with tafamidis was initiated in about 80% of patients with newly diagnosed ATTR-CM. In most centres, treatment decisions were made by an interdisciplinary board, and the reasons for treatment decisions were similar across centres. Due to the lack of consensus criteria, our data may help to standardise decision pathways for ATTR-CM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02848-z","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T09:59:07Z","timestamp":1769421547000},"page":"862-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current treatment decisions in cardiac transthyretin amyloidosis: a multicentre analysis"],"prefix":"10.1007","volume":"115","author":[{"given":"Daniel","family":"Lavall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2339-591X","authenticated-orcid":false,"given":"Katharina","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Spethmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Barzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim B.","family":"Winzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Jellinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Sch\u00f6ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Tr\u00f6bs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Kauffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Donhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara S.","family":"Schlender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Leistner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"A\u00dfmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Uns\u00f6ld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"B\u00fchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"aus dem Siepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Kindermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Majunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"M\u00fcller-Kozarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie K.","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliyan","family":"Metodiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selen","family":"Alieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Zlibut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Mustroph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tafelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Papagianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J.","family":"Steinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Cejka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"issue":"1","key":"2848_CR1","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM et al (2020) Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation 142(1):e7\u2013e22","journal-title":"Circulation"},{"issue":"16","key":"2848_CR2","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42(16):1554\u20131568","journal-title":"Eur Heart J"},{"issue":"38","key":"2848_CR3","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E et al (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585\u20132594","journal-title":"Eur Heart J"},{"issue":"9","key":"2848_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS (2024) Cardiac amyloidosis due to transthyretin protein: a review. JAMA 331(9):778\u2013791","journal-title":"JAMA"},{"issue":"11","key":"2848_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"2","key":"2848_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD et al (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390(2):132\u2013142","journal-title":"N Engl J Med"},{"key":"2848_CR7","doi-asserted-by":"publisher","unstructured":"Fontana M et al (2025) Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 392(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134. Accessed 30 Aug 2024","DOI":"10.1056\/NEJMoa2409134"},{"issue":"3","key":"2848_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P et al (2023) Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med 389(3):239\u2013250","journal-title":"N Engl J Med"},{"issue":"6","key":"2848_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101667","volume":"48","author":"A Ghoneem","year":"2023","unstructured":"Ghoneem A et al (2023) Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure. Curr Probl Cardiol 48(6):101667","journal-title":"Curr Probl Cardiol"},{"key":"2848_CR10","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P et al (2025) Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). J Card Fail\u00a031(3):525\u2013533. https:\/\/doi.org\/10.1016\/j.cardfail.2024.06.003. Accessed 21 Jun 2024","DOI":"10.1016\/j.cardfail.2024.06.003"},{"issue":"15","key":"2848_CR11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS et al (2020) Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation 141(15):1214\u20131224","journal-title":"Circulation"},{"issue":"30","key":"2848_CR12","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD et al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799\u20132806","journal-title":"Eur Heart J"},{"issue":"7","key":"2848_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","volume":"86","author":"Y Ochi","year":"2022","unstructured":"Ochi Y et al (2022) Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort. Circ J 86(7):1121\u20131128","journal-title":"Circ J"},{"issue":"12","key":"2848_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101358","volume":"47","author":"K Hussain","year":"2022","unstructured":"Hussain K et al (2022) Impact of tafamidis on survival in a real-world community-based cohort. Curr Probl Cardiol 47(12):101358","journal-title":"Curr Probl Cardiol"},{"key":"2848_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.hjc.2023.09.019","volume":"79","author":"D Bampatsias","year":"2024","unstructured":"Bampatsias D et al (2024) Transthyretin amyloidosis cardiomyopathy in Greece: clinical insights from the National Referral Center. Hellenic J Cardiol 79:25\u201334","journal-title":"Hellenic J Cardiol"},{"issue":"2","key":"2848_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40256-022-00563-4","volume":"23","author":"R Bhambri","year":"2023","unstructured":"Bhambri R et al (2023) Real-world characteristics of patients with wild-type transthyretin amyloid cardiomyopathy: an analysis of electronic healthcare records in the United States. Am J Cardiovasc Drugs 23(2):197\u2013206","journal-title":"Am J Cardiovasc Drugs"},{"key":"2848_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15126","author":"RJ Nies","year":"2024","unstructured":"Nies RJ et al (2024) Real-world characteristics and treatment of cardiac transthyretin amyloidosis: a multicentre, observational study. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.15126","journal-title":"ESC Heart Fail"},{"issue":"5","key":"2848_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00392-023-02163-x","volume":"113","author":"C Morbach","year":"2024","unstructured":"Morbach C et al (2024) Tafamidis for cardiac transthyretin amyloidosis: application in a real-world setting in Germany. Clin Res Cardiol 113(5):653\u2013655","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"2848_CR19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","volume":"46","author":"E Gonzalez-Lopez","year":"2025","unstructured":"Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P (2025) Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J 46(11):999\u20131013","journal-title":"Eur Heart J"},{"issue":"22","key":"2848_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A et al (2022) Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146(22):1657\u20131670","journal-title":"Circulation"},{"issue":"11","key":"2848_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/eurheartj\/ehae923","volume":"46","author":"P Debonnaire","year":"2025","unstructured":"Debonnaire P et al (2025) Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study. Eur Heart J 46(11):1057\u20131070","journal-title":"Eur Heart J"},{"issue":"37","key":"2848_CR22","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E et al (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503\u20133626","journal-title":"Eur Heart J"},{"issue":"2","key":"2848_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cardfail.2013.12.003","volume":"20","author":"DJ Whellan","year":"2014","unstructured":"Whellan DJ et al (2014) End-of-life care in patients with heart failure. J Card Fail 20(2):121\u2013134","journal-title":"J Card Fail"},{"key":"2848_CR24","doi-asserted-by":"crossref","unstructured":"McDonagh TA et al (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 2022. 24(1):4\u2013131","DOI":"10.1002\/ejhf.2333"},{"issue":"11","key":"2848_CR25","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ejhf.2974","volume":"25","author":"P Elliott","year":"2023","unstructured":"Elliott P et al (2023) Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms. Eur J Heart Fail 25(11):2060\u20132064","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2848_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamacardio.2022.5251","volume":"8","author":"BW Sperry","year":"2023","unstructured":"Sperry BW et al (2023) Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol 8(3):275\u2013280","journal-title":"JAMA Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02848-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02848-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02848-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:26:17Z","timestamp":1782743177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02848-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2848"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02848-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update of the supplementary material.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective, multicentre study was conducted retrospectively from data obtained for clinical purposes. All study centres obtained local ethical or institutional review board approval for their local registries. The study was performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"D.L. received speaker and\/or consulting fees from Pfizer, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Alnylam, and AstraZeneca. K.K. report speaker, consulting fees, and\/or travel grants from Pfizer, Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, and Bristol Myers Squibb. K.H. has received funding by Alnylam Pharmaceuticals Inc., Pfizer Pharmaceuticals, and Berlin Institute of Health (BIH), funding unrelated to this article. K. H. received financial reimbursement for consulting, advisory board activities, speaker fees and\/or contributions to congresses, and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Amicus, AstraZeneca, GSK, Hormosan, Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc., and Swedish Orphan Biovitrum Inc., and ViiV Healthcare GmbH. K. H. received financial reimbursement for consulting, advisory board activities, speaker fees and\/or contributions to congresses, and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Amicus, AstraZeneca, GSK, Hormosan, Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc., and Swedish Orphan Biovitrum Inc., and ViiV Healthcare GmbH. S.S. received consulting fees, advisory board fees, lecture fees, research funding, and travel grants for participation in scientific meetings from Pfizer Pharma GmbH, Alnylam Netherlands BV, Bayer Vital GmbH, Boehringer Ingelheim Pharma GmbH, Edwards Lifesciences, and AstraZeneca GmbH, which were not related to this project. G.B. has received funding by Alnylam Pharmaceuticals Inc. unrelated to this article. G.B. received lecture fees, research funding, and travel reimbursement by Alnylam Pharmaceuticals, Intellia Therapeutics, and AstraZeneca. E.B.W. reported grants from Boehringer Ingelheim and personal fees from Amarin, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, CVRx, Daiichi Sankyo, Novartis, Novo Nordisk, and Pfizer outside the submitted work. L.K.S. reported grants from Pfizer and Alnalym outside the submitted work. S.J. reported personal fees from Amgen, Daiichi Sankyo, Abbott, Medtronic, Abiomed, and Sanofi Aventis outside the submitted work. M.T. received speaker and\/or consulting fees from Pfizer, Abbott, Bristol Myers Squibb, Alnylam, and AstraZeneca. L.M.: personal fees outside the submitted work from Bayer, Bristol Myers Squibb, Alnylam, AstraZeneca, IFFM e. V. and from Bund der Niedergelassenen Kardiologen (BNK). J.V.: personal fees outside the submitted work from Eli Lilly, Bayer, Alnylam, and Pfizer. Research funding: UMEA Clinician Scientist Scholarship from the Faculty of Medicine, University of Duisburg-Essen and Bayer for an investigator\/institution sponsored collaborative study outside the submitted work. T.R. has received honoraria, lecture fees, and grant support from Edwards Lifesciences, AstraZeneca, Bayer, Novartis, Berlin Chemie, Daiicho-Sankyo, Boehringer Ingelheim, Novo Nordisk, Cardiac Dimensions, and Pfizer, all unrelated to this work. He is co-founder of Bimyo GmbH, a company that develops cardioprotective peptides and a co-founder of myCor GmbH, a company focusing on the development of ECG-algorithms to detect patients with amyloidosis. F.S. reports speaker fees and\/or consulting fees from Pfizer, Alnylam, Bayer, Neurimmune, AstraZeneca, and NovoNordisc. I.K. reports consulting fees, advisory, and speakers honoraria as well as travel grants from Pharmacosmos GmbH, Pfizer Pharma GmbH, Bristol- Myers-Squibb, Daiichi Sankyo, Akcea Therapeutics Germany GmbH, Vifor Pharma Deutschland, Novartis Pharma GmbH, Servier Deutschland GmbH, AstraZeneca GmbH, Bayer Vital GmbH, Daiichi Sankyo, Alnylam, SOBI, Diaplan, Boehringer- Ingelheim Pharma GmbH &Co.KG, Orionpharma, Scirac. I.K. serves as principal investigator in trials sponsored by IONIS Pharmaceuticals, Alexion Pharmaceuticals, and AstraZeneca. B.U. reports speaker and consulting fees from Pfizer, Alnylam, Sobi, AstraZeneca und Bayer. R.P. reports speaker fees and travel grants from Pfizer, Alnylam, AstraZeneca, Bayer, and NovoNordisk. Further, he received a research grant by Pfizer. S.K.S. reports speaker and consulting fees from Pfizer, Alnylam, AstraZeneca, and Bayer and serves as principal investigator in trials sponsored by Bayer, NovoNordisk, Intellia, AstraZeneca, and Alexion. A.Y. reports speakers and consulting fees from Alnylam, Bayer, Philips, GE, AstraZeneca, BridgeBio, NovoNordisk, Alexion und Pfizer as well as research cooperations with Philips und Circle. J.M. reports speaker fees for talks related to cardiac amyloidosis and\/or hypertrophic cardiomyopathy by Bayer, Bristol Myers Squibb, and AstraZeneca. A.P. report speaker, consulting fees and\/or travel grants from Pfizer, Alnylam, AstraZeneca, and SoBi outside the submitted work. V.C. reports sponsoring of attendance and travel to scientific congresses from Lily, Boheringer Ingelheim, and Alnylam. He has received lecturing fees from Pfizer. C. M. reports research cooperation with the University of W\u00fcrzburg and Tomtec Imaging Systems funded by a research grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy, German Germany (MED-1811\u20130011, LSM-2104\u20130002, and LSM-2403\u20130005); C.M. further received advisory and speakers honoraria as well as travel grants from Tomtec, Edwards, Alnylam, Pfizer, Boehringer Ingelheim, Eli Lilly, SOBI, AstraZeneca, NovoNordisk, Alexion, Janssen, Bayer, Intellia, and EBR Systems; she serves as principal investigator in trials sponsored by Alnylam, Bayer, NovoNordisk, Intellia, and AstraZeneca. T.T. reports speaker and travel grants: Pfizer, Alnylam, Zoll, Novartis, Astra Zeneca, Alexion, Bayer, Bristol Myers Squibb, Zoll, and Boehringer Ingelheim. B.H. received speaker fees from Pfizer Pharmaceuticals Inc. and AstraZeneca, as well as research grant from Pfizer Pharmaceuticals Inc. unrelated to this project. D.K., N.D., M.P., L.S.S., D.M.L., B.A., L.B., E.H., C.N., A.Z., M.S., N.M., I.M., Y.M., S.A., A.Z., M.T., T.K., and M.J.S. report no conflicts of interest relevant to the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}